UK Markets close in 2 hrs 26 mins

Boston Scientific Corporation (BSX)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
38.73-0.61 (-1.55%)
At close: 04:00PM EDT
38.94 +0.21 (+0.54%)
Pre-market: 08:44AM EDT

Boston Scientific Corporation

300 Boston Scientific Way
Marlborough, MA 01752-1234
United States
508 683 4000
https://www.bostonscientific.com

Sector(s)Healthcare
IndustryMedical Devices
Full-time employees41,000

Key executives

NameTitlePayExercisedYear born
Mr. Michael F. MahoneyChairman, Pres & CEO3.83MN/A1965
Mr. Daniel J. BrennanExec. VP & CFO1.4M796.81k1966
Mr. Joseph M. FitzgeraldExec. VP & Group Pres of Cardiology1.57M2.72M1964
Mr. Jeffrey B. MirvissExec. VP & Pres of Peripheral Interventions1.21M2.75M1966
Mr. John Bradley SorensonExec. VP of Global OperationsN/AN/A1968
Mr. Jonathan R MonsonVP, Global Controller & Chief Accounting OfficerN/AN/AN/A
Ms. Jodi Euerle EddySr. VP and Chief Information & Digital OfficerN/AN/A1973
Ms. Susan Vissers LisaVP of Investor RelationsN/AN/A1969
Mr. Vance R. BrownSr. VP, Gen. Counsel & Corp. Sec.N/AN/AN/A
Ms. Catherine JenningsVP of Global Marketing & New Bus. Devel. of Peripheral InterventionsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Corporate governance

Boston Scientific Corporation’s ISS governance QualityScore as of 1 July 2022 is 7. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.